Ginkgo Bioworks Holdings (DNA) Interest Expenses (2019 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Interest Expenses came in at $2.9 million in Q1 2026, up 8.24% YoY from $2.7 million in Q1 2025, and down 99.65% on a QoQ basis from $840.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Interest Expenses (2019 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 8 years of Interest Expenses data on file, last reported at $2.9 million in Q1 2026.
- Quarterly Interest Expenses rose 8.24% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 8.24% YoY) and the FY2025 annual result came in at $840.1 million, up 8.84% from the prior year.
- Interest Expenses slipped to $2.9 million in Q1 2026, from $840.1 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $840.1 million in Q4 2025 to a low of -$15.0 million in Q3 2023.
- A 5-year average of $166.3 million and a median of $38.1 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 151095.28% — and 2023, when it sank 129.51%.
- Tracing DNA's Interest Expenses over 5 years: stood at $833.1 million in 2022, then tumbled by 89.44% to $88.0 million in 2023, then decreased by 13.27% to $76.3 million in 2024, then soared by 1001.08% to $840.1 million in 2025, then slumped by 99.65% to $2.9 million in 2026.
- The last three Interest Expenses figures came in at $2.9 million (Q1 2026), $840.1 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 2.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.92 Mn |
| Jun 30, 2026 | 2.92 Mn |
| Mar 31, 2026 | 2.94 Mn |
| Mar 31, 2026 | 2.94 Mn |
| Dec 31, 2025 | 840.06 Mn |
| Dec 31, 2025 | 840.06 Mn |
| Sep 30, 2025 | 2.98 Mn |
| Sep 30, 2025 | 2.98 Mn |
| Jun 30, 2025 | 2.98 Mn |
| Jun 30, 2025 | 2.98 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | 76.29 Mn |
| Dec 31, 2024 | 76.29 Mn |
| Sep 30, 2024 | -9.25 Mn |
| Sep 30, 2024 | -9.25 Mn |
| Jun 30, 2024 | -10.31 Mn |
| Jun 30, 2024 | -10.31 Mn |
| Mar 31, 2024 | 768.00 Mn |
| Mar 31, 2024 | 768.00 Mn |